VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Price & Overview
BIT:1VRTX • US92532F1003
The current stock price of 1VRTX.MI is 334.7 EUR. Today 1VRTX.MI is down by -0.61%. In the past month the price decreased by -11.72%.
1VRTX.MI Key Statistics
- Market Cap
- 85.814B
- P/E
- 23.19
- Fwd P/E
- 18.76
- EPS (TTM)
- 14.43
- Dividend Yield
- N/A
1VRTX.MI Stock Performance
1VRTX.MI Stock Chart
1VRTX.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1VRTX.MI.
1VRTX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1VRTX.MI. 1VRTX.MI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
1VRTX.MI Earnings
On August 4, 2025 1VRTX.MI reported an EPS of 4.52 and a revenue of 2.96B. The company beat EPS expectations (3.45% surprise) and beat revenue expectations (0.06% surprise).
1VRTX.MI Forecast & Estimates
39 analysts have analysed 1VRTX.MI and the average price target is 416.5 EUR. This implies a price increase of 24.44% is expected in the next year compared to the current price of 334.7.
For the next year, analysts expect an EPS growth of 6256.61% and a revenue growth 10.03% for 1VRTX.MI
1VRTX.MI Groups
Sector & Classification
1VRTX.MI Financial Highlights
Over the last trailing twelve months 1VRTX.MI reported a non-GAAP Earnings per Share(EPS) of 14.43. The EPS increased by 7966.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.86% | ||
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0 |
1VRTX.MI Ownership
1VRTX.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.33 | 39.779B | ||
| ARGX | ARGENX SE | 24.32 | 39.754B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.871B | ||
| ABVX | ABIVAX SA | N/A | 7.868B | ||
| 2X1 | ABIVAX SA | N/A | 7.844B | ||
| GLPG | GALAPAGOS NV | N/A | 1.886B | ||
| GXE | GALAPAGOS NV | N/A | 1.883B | ||
| NANO | NANOBIOTIX | N/A | 1.398B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.061B | ||
| PHIL | PHILOGEN SPA | 16.81 | 615.502M | ||
| GNFT | GENFIT | N/A | 431.775M | ||
| AYJ | VALNEVA SE | N/A | 408.046M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1VRTX.MI
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / 1VRTX.MI FAQ
Can you describe the business of VERTEX PHARMACEUTICALS INC?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
What is the current price of 1VRTX stock?
The current stock price of 1VRTX.MI is 334.7 EUR. The price decreased by -0.61% in the last trading session.
Does 1VRTX stock pay dividends?
1VRTX.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1VRTX stock?
1VRTX.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the market cap for VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) has a market capitalization of 85.81B EUR. This makes 1VRTX.MI a Large Cap stock.
Can you provide the upcoming earnings date for VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) will report earnings on 2025-11-03, after the market close.